The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Ruben A. Mesa
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 1
Which of the following is true of anemia in patients with myelofibrosis?
A
B
C
D
During the MPN Hub Steering Committee meeting, Ruben Mesa discussed anemia as an unmet need and the impact on quality of life and survival outcomes in patients with myelofibrosis (MF).
Anemia as an unmet need: Impacts on QoL and survival outcomes
Anemia as an unmet need: Impacts on QoL and survival outcomes
Key points
Anemia in patients with MF is a complex, multifactorial process, and can be exacerbated by treatment with some Janus kinase inhibitors, including ruxolitinib and fedratinib.1,2
Anemia is common in patients with primary MF, with one study reporting hemoglobin levels <10 g/dL in 38% of patients at the time of diagnosis, increasing to 58% in patients seen within 1 year since diagnosis.3
Anemia can negatively impact overall survival; in a study of 1,109 consecutive patients with primary MF, the median overall survival among patients with no, mild, moderate, and severe anemia was 7.9 years, 4.9 years, 3.4 years, and 2.1 years, respectively.4
Anemia also negatively impacts patients' quality of life; a study of 85 patients with MF showed that anemia responders had greater improvements in quality of life vs nonresponders.5
There is a need for effective treatments to address MF-related anemia.
This educational resource is independently supported by GSK and Bristol Myers Squibb. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
More from this series:
MPN Hub Steering Committee discussion: Treating anemia in patients with myelofibrosis
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?